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Abstract
Background: Cytochalasin B does not directly activate the oxygen-radical-producing NADPH
oxidase activity of neutrophils but transfers desensitized G-protein coupled receptors (GPCR) into
an active signaling state by uncoupling GCPR from the cytoskeleton. The receptor uncoupling
results in respiratory burst activity when signals generated by reactivated formyl peptide receptors
trigger the NADPH-oxidase to produce superoxide anions.
Results: Tumor necrosis factor alpha (TNF-alpha) primes neutrophils for subsequent activation by
cytochalasin B. Pretreatment with TNF-alpha induced mobilization of receptor-storing neutrophil
organelles, suggesting that receptor up-regulation significantly contributes to the response, but the
receptor mobilization was not sufficient for induction of the cytochalasin B sensitive state. The
TNF-alpha primed state resembled that of the desensitized non-signaling state of agonist-occupied
neutrophil formyl peptide receptors. The fact that the TNF-alpha primed, cytochalasin B-triggered
activation process was pertussis toxin sensitive suggests that the activation process involves a
GPCR. Based on desensitization experiments the unidentified receptor was found to be distinct
from the C5a receptor as well as the formyl peptide receptor family members FPR and FPRL1.
Based on the fact the occupied and desensitized receptors for interleukin-8 and platelet activating
factor could not be reactivated by cytochalasin B, also these could be excluded as receptor
candidates involved in the TNF-alpha primed state.
Conclusions:  The TNF-alpha-induced priming signals could possibly trigger a release of an
endogenous GPCR-agonist, amplifying the response to the receptor-uncoupling effect of
cytochalasin B. However, no such substance could be found, suggesting that TNF-alpha can transfer
G-protein coupled receptors to a signaling state independently of agonist binding.
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Background
Human neutrophil granulocytes constitute an important
part of the innate immune defense against microbial
infections, and the bactericidal activities performed by
these cells rely on their interaction with chemoattractants,
cytokines and other inflammatory mediators [1]. The che-
moattractants, including C5a, platelet activating factor
(PAF), interleukin-8 (IL8) and formylated peptides, bind
to specific receptors [2,3], all of which belong to a family
of transmembrane G-protein coupled receptors (GPCRs).
Activation of these receptors leads to directed migration,
granule mobilization and activation of the neutrophil
NADPH-oxidase [2]. The reactive oxygen species gener-
ated by the oxidase are of importance for microbial killing
and for cell-cell-signaling [4].
Tumor necrosis factor-alpha (TNF-α) is one of the earliest
cytokines produced at inflammatory sites by activated
monocytes and macrophages. This cytokine affects neu-
trophil function mainly through binding to type I TNF
receptor (TNFR1) [5]. The TNFR1 is a single transmem-
brane glycoprotein with several intracellular motifs with
known functional significance, but it is not linked to any
signaling G-protein [5-7]. Phosphorylation of TNFR1
occurs at a consensus MAPK site on its cytoplasmic
domain or through tyrosine phosphorylation [6,7],
although it is not fully understood how this phosphoryla-
tion control receptor signaling or processing.
The biological effects of TNF-α on neutrophil functions in
vitro vary, as illustrated by the ability or inability of TNF-α
to affect the neutrophil oxygen radical producing
NADPH-oxidase. In order for TNF-α to trigger neutrophil
superoxide production, cells need to adhere to a solid sur-
face, and the magnitude of the response is determined by
which protein that is coated on the surface [8]. TNF-α only
weakly triggers the oxidase when the neutrophils are in
suspension [8]; however, after exposure to TNF-α, these
cells are primed with respect to NADPH-oxidase activa-
tion in response to other stimuli [9]. Thus, while TNF-α
per se does not activate the NADPH-oxidase to any signif-
icant extent in nonadherent neutrophils, it induces a state
of hyper-responsiveness to other stimuli.
Several mechanisms have been proposed to account for
neutrophil priming [10-14], including receptor mobiliza-
tion from intracellular granule stores [15-17]. The aim of
this study was to characterize the primed state induced in
human neutrophils by TNF-α, using an earlier described
receptor uncoupling system [18]. We found exposure of
new receptors to be a part of the priming process, but
more importantly we found that neutrophils interacting
with TNF-α were transferred into a novel state, in which
the cytoskeleton disrupting compound cytochalasin B
triggered activation. The TNF-α primed state shows many
similarities with that of neutrophils that have their formyl
peptide GPCRs desensitized by a specific receptor agonist
[18]. Isomerization of GPCRs, from an inactive to an
active state, occurs normally as a result of ligand binding
but can also occur independently of agonist [19] and our
findings are suggestive of a TNF-α induced novel activa-
tion mechanism that is receptor agonist-independent.
Results
TNF-α primes the neutrophil NADPH-oxidase response to 
a subsequent stimulation/triggering with cytochalasin B
Cytochalasin B, a cytoskeleton disrupting compound,
does not induce a neutrophil response by itself [18] but is
known to augment the neutrophil response to many stim-
uli. We investigated whether this was true also for the
minimal neutrophil response induced by a direct stimula-
tion with TNF-α. We found that cytochalasin B had no
effect on the NADPH-oxidase response when added to
neutrophils prior to TNF-α treatment (data not shown).
However, when the cells were first treated with TNF-α and
subsequently challenged with cytochalasin B, a pro-
nounced respiratory burst activity was noted (Fig 1). The
time course of the induced response was similar to that
seen with chemoattractants such as the formylated pep-
tide fMLF, an agonist that activates cells through the G-
protein coupled formyl peptide receptor, FPR. The peak of
activity was reached 1–2 minutes after the addition of
cytochalasin B and the response then rapidly declined to
reach a base-line level after 3–4 min that remained con-
stant throughout the observation period.
In agreement with the results reported by others [8,9] we
found that TNF-α alone only poorly activated the neu-
trophil NADPH-oxidase, determined as the release of
superoxide anions (3.2 ± 0.3 × 106 cpm; mean peak value
± SD, n = 3; corresponding to a maximum value that was
less than 5% of that induced by fMLF). The oxidase activ-
ity induced by cytochalasin B in TNF-α-treated cells was of
the same magnitude as that triggered by fMLF (Figs 1 and
2). In agreement with previous reports [20-22], TNF-α was
found to prime neutrophils to a subsequent stimulation
with fMLF (Fig 2).
The level of superoxide production induced by cytochala-
sin B was dependent on the concentration of TNF-α. (Fig
1) as well as on the duration of TNF-preactivation. When
the time between the addition of TNF-α and cytochalasin
B was less than 5 minutes, no respiratory burst activity was
observed upon cytochalasin B challenge. The response to
cytochalasin B gradually increased with the time allowed
for TNF-α to interact with the neutrophils, reaching a pla-
teau after approximately 20 min (Fig 3). The protein syn-
thesis inhibitor cycloheximide did not inhibit the
cytochalasin B-induced NADPH-oxidase activity in TNF-α
primed cells (data not shown), suggesting that de novoBMC Cell Biology 2004, 5 http://www.biomedcentral.com/1471-2121/5/21
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protein synthesis was not required for the observed neu-
trophil activation.
Reactivation of deactivated GPCR has implications for 
TNF-α priming
All neutrophil chemoattractant receptors including C5aR
(for the complement component C5aR), PAFR (for plate-
let activating factor), CXCR1 and 2 (for IL-8), FPR (for
fMLF) and FPRL1 (for WKYMVM) belong to the GPCR
family [2]. Interaction between these receptors and their
respective ligands results in activation of the neutrophil
NADPH-oxidase (Table 1). Neutrophils that were allowed
to interact with either of these agonists at 15°C and then
transferred to 37°C became deactivated, i.e., there was no
burst in oxidase activity, and the cells did not respond to
further stimulation with the same chemoattractant. Fur-
thermore, cytochalasin B induced a robust burst of oxi-
dase activity in C5a- as well as in fMLF- and WKYMVM-
deactivated cells i.e., these cells (or rather the FPR, FPRL1
and C5aR) were reactivated. In contrast, no such reactiva-
tion was induced by cytochalasin B in IL-8 or in PAF deac-
tivated cells (Table 1).
The cytochalasin B induced superoxide production in
TNF-α-primed neutrophils is similar to that induced by
uncoupling and reactivation of occupied and deactivated
FPR, FPRL1 or C5aR from the cytoskeleton, induced by
the same drug. The most direct interpretation of these
results is therefore that the TNF-α primed cells express a
GPCR, of hitherto unknown identity, which gradually
becomes occupied and then deactivated. When
uncoupled from the cytoskeleton by cytochalasin B, the
receptor is reactivated and the signals generated induce an
activation of the oxidase. To test this hypothesis, we pre-
treated the cells with pertussis toxin, which inactivates the
heterotrimeric G-proteins coupled to the GPCRs. Since no
NADPH-oxidase activity could be induced by cytochala-
sin B in TNF-α primed cells that were first treated with per-
tussis toxin (Fig 4), our hypothesis is valid, i.e., a GPCR is
involved in the TNF-α-primed cytochalasin B response. It
should be noted that pertussis toxin had no effect on the
Cytochalasin B stimulation of TNF-α primed neutrophils Figure 1
Cytochalasin B stimulation of TNF-α primed neu-
trophils. Neutrophils were pre-incubated with TNF-α (25 
ng/ml, 20 min, 37°C) after which they were stimulated with 
cytochalasin B The extracellular release of superoxide anions 
was measured by isoluminol-amplifled chemiluminescence 
(CL) given as Mcpm (106 counts per minutes). The figure 
shows the kinetics of a representative experiment. The indi-
cated value shows the mean peak value ± SD, n = 3. The abil-
ity of cytochalasin B to induce NADPH-oxidase activity was 
dependent on the priming concentration of TNF-α (inset; 
comparing the peak values of the responses at varying con-
centrations to the value obtained with 25 ng/ml of TNF-α).
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fMLF stimulation of TNF-α primed neutrophils Figure 2
fMLF stimulation of TNF-α primed neutrophils. Neu-
trophils were pre-incubated in the absence (dashed line) or 
presence (solid line) of TNF-α (25 ng/ml) for 20 min at 37°C 
after which they were stimulated with fMLF. The extracellu-
lar production of superoxide anion after addition of the pep-
tide (10-7M) was measured by isoluminol-amplified CL. 
Responses of CL are given as Mcpm (106 counts per min-
utes). The figure shows the kinetics of representative 
experiments.
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ability of TNF-α to mobilize CR3 to the neutrophil surface
(Fig 4). On the basis of these results, we hypothesized that
a preformed endogenous agonist may be released from
neutrophils during interaction with TNF-α, and we there-
fore attempted to verify the existence of such an agonist.
Cytochalasin B induced reactivation of FPR is inhibited by 
the receptor antagonist cyclosporine H
To test the hypothesis of an endogenous GPCR-agonist,
we first determined the basic reactivation characteristics of
occupied and desensitized receptors, using a model
system in which desensitized neutrophils were pre-incu-
bated with fMLF at 15°C. When pre-warmed neutrophils
(37°C for 20 min) were added to a measuring system con-
taining desensitized cells, the oxidase of the non-desensi-
tized cells was activated, suggesting that free ligands are
present in the measuring system (data not shown). In
order to determine if these free ligands are of importance
for the FPR reactivation induced by cytochalasin B, we
added the receptor specific antagonist cyclosporine H to
fMLF-desensitized cells a few seconds before cytochalasin
B. In agreement with the specificity of the antagonist for
FPR, a reduced NADPH-oxidase activity was obtained. No
such inhibition by cyclosporine H was seen upon reactiva-
tion, when using cells that were incubated with the FPRL1
specific agonist WKYMVM or TNF-α (Fig 5).
Moreover, when the fMLF specific desensitization proce-
dure was performed in a dense cell population (107 cells/
ml desensitized with 10-7M fMLF) and the cells were
diluted to 105 cells/ml in pre-warmed measuring vials
containing either a high concentration of peptide (final
concentration of fMLF being 10-7M) or no peptide (final
concentration of fMLF being 10-9M), the addition of cyto-
chalasin B induced a burst in NADPH-oxidase activity
only in samples with a high concentration of fMLF (Fig 6).
Taken together these results suggest that in order for cyto-
chalasin B to function as an inducer of respiratory burst,
the fMLF desensitized neutrophils have to be continu-
ously exposed to a high concentration of free ligand.
Time dependency of the TNF-α effect Figure 3
Time dependency of the TNF-α effect Responses to 
cytochalasin B after incubation with TNF-α for different peri-
ods of time. Neutrophils were pre-incubated with TNF-α (25 
ng/ml, 37°C) under various time-periods (5–40 min), before 
they were stimulated with cytochalasin B. The production of 
superoxide anions was measured by isoluminol-amplified CL 
as described above.
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Pertussis toxin (PtX) sensitivity of cytochalasin B induced  superoxide anion production and CR3 upregulation in TNF- α primed neutrophils Figure 4
Pertussis toxin (PtX) sensitivity of cytochalasin B 
induced superoxide anion production and CR3 upreg-
ulation in TNF-α primed neutrophils. Neutrophils were 
preincubated with TNF-α (25 ng/ml, 20 min, 37°C) before 
they were incubated with PtX (500 ng/ml) for various time-
periods (20–140 min). The cells were either paraformalde-
hyde-fixed and analyzed by flow cytometry for CR3 upregula-
tion (closed squares), or stimulated with cytochalasin B, and 
the superoxide anion production were measured by CL 
(open squares). All analyzed populations of PtX incubated 
cells were compared to TNF-α primed cells not exposed to 
PtX.
0
20
40
60
80
100
120
0 20 40 60 80 100 120 140 160
Preincubation time with PtX
(min)
%
o
f
c
o
n
t
r
o
lBMC Cell Biology 2004, 5 http://www.biomedcentral.com/1471-2121/5/21
Page 5 of 14
(page number not for citation purposes)
No endogenous neutrophil activator can be identified 
following incubation with TNF-α
Neutrophils contain several preformed agonists/chemoat-
tractants [23,24] that could participate in an autocrine
amplification loop. As described above, binding of neu-
trophil chemoattractants to their respective neutrophil
receptors induces a rapid desensitization of the receptor,
leading to an inability of the cells to respond to a second
challenge by the same agonist. Accordingly, if TNF-α
would induce secretion of an autocrine activator, this
should be expected to induce a desensitized state of the
specific receptor population involved. The finding that
TNF-α triggered cells were primed rather than desensi-
tized to fMLF, WKYMVM/m and C5a, suggests that the
potential endogenous utilizes neither FPR, FPRL1 nor
C5aR.
To identify the hypothetical endogenous agonist, we pre-
pared cell free supernatants of TNF-α treated neutrophils
and added these to new populations of primed or
unprimed cells. No oxidase activation could be induced
by compounds secreted from the TNF-α primed cells
(data not shown). As stated above, neutrophils added to a
population of fMLF desensitized cells were rapidly acti-
vated to generate superoxide by the fMLF present in the
medium. When repeating this experiment with TNF-
primed instead of fMLF desensitized cells, no such activity
was seen (Fig 7). Furthermore, the newly added cells (non
TNF-α primed) were not triggered by the addition of cyto-
chalasin B (Fig 7), as illustrated by the finding that the
NADPH-oxidase activity in mixed population of cells
(50% primed and 50% non-primed) was only half of that
of a cell population (with the same number of cells) in
which all the cells were primed. Taken together these data
suggest that no free agonist is present in the TNF-α primed
cell suspension that could be responsible for transfer of
the cells into a cytochalasin B-sensitive state.
TNF-α induces mobilization of receptor-storing granules
Previous studies have shown that different receptor struc-
tures as well as potential activating agonists are stored in
secretory granules of peripheral blood neutrophils
[17,25,26], suggesting that mobilization of these
organelles will prime neutrophils to certain stimuli. We
monitored the amount of the complement receptor 3
(CR3) and found that TNF-α-primed cells exposed an
increased number of CR3 on their surface (Fig 8). In
addition, TNF-α priming was accompanied by an
increased specific binding of radiolabeled fMLF (10.2 ±
3.3 moles/106cells bound to TNF-α treated cells com-
pared to 4.0 ± 1.6 fmoles/106 cells for corresponding con-
trol cells; mean ± SEM, n = 6), reflecting an increased
amount of formyl peptide receptors (FPR) on the neu-
trophil surface. Hence, FPR and integrin-storing
organelles were significantly mobilized upon treatment of
neutrophils with TNF-α. We also found it of interest to
determine whether induction of the cytochalasin B sensi-
tive state is unique for TNF-α, or if it occurs also with other
secretagogues. To investigate the precise role of granule
mobilization in induction of the cytochalasin B sensitive
state, we monitored the amount of the complement recep-
tor 3 (CR3) on the surface of neutrophils. The finding that
neutrophil receptors for IL-8 were not reactivated by cyto-
chalasin B (Table 1) suggested that IL-8 is a suitable con-
trol priming agent in these experiments. No respiratory
burst was obtained in response to cytochalasin B when
TNF-α was replaced by IL-8 (Table 1), despite an induc-
tion of storage organelle mobilization also by IL-8 (Fig 9).
It should be pointed out that the activation potency in
relation to cytochalasin B was retained also when the con-
centration of TNF-α was reduced to concentrations that
gave a level of CR3 mobilization similar to that induced
by IL-8.
Table 1: Deactivation/reactivation properties of classical chemoattractants and their receptors.
Effects on the neutrophil NADPH-oxidase*
Agonist (conc.) Receptor(s) Activation Deactivation Reactivation
fMLF (l0-7M ) F P R +++
WKYMVM (10-7M ) F P R L 1 +++
C5a (100 ng/ml) C5aR + + +
PAF (10-7M) PAFR + + -
IL8 (100 ng/ml) CXCR 1/2 + + -
*Indicated chemoattractants were used to stimulate human neutrophils directly (activation), or added to the cells at 15 (according to the protocol 
described in Methods) after which these cells were transferred to 37 and stimulated with the same agonist (deactivation) or reactivated with 
cytochalasin B (reactivation). The superoxide anion production was measured by isolummol-enhanced CL. The + and - indicate whether or not the 
process occurred. The experiments were repeated between 2–10 times.BMC Cell Biology 2004, 5 http://www.biomedcentral.com/1471-2121/5/21
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Cyclosporin H sensitivity of cytochalasin B induced superoxide anion production in fMLF desensitized, WKYMVM desensitized  or TNF-α primed neutrophils Figure 5
Cyclosporin H sensitivity of cytochalasin B induced superoxide anion production in fMLF desensitized, 
WKYMVM desensitized or TNF-α primed neutrophils. Neutrophils were preincubated with fMLF (10-7M; 10 min A), 
WKYMVM (10-7M; 10 min B) or TNF-α (25 ng/ml; 20 min C). The cells were challenged with cytochalasin B in samples without 
(solid lines) and with cyclosporine H (final concentration in A, 10-7M and in B and C, 10-6M; dashed lines) that was added 1 min 
before cytochalasin B. The production of superoxide anions was measured by isoluminol-amplified CL as described above. The 
figure shows the kinetics of representative experiments and the ratios between the peak response in the absence and presence 
of cyclosporine H are given.
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Effects of the MAPK inhibitor SB 203580
There is a well described link between TNF-α-induced
activation of the p38 mitogen-activated protein kinase
(MAPK) and superoxide anion formation in adherent
neutrophils (reviewed by Berton [27]). We investigated
the effect of the specific p38 MAPK inhibitor SB203580 in
our model system. As shown in Fig 8, SB203580 signifi-
cantly attenuated the TNF-α priming, whereas no reduc-
tion was observed when neutrophils were first incubated
with SB203580 and then stimulated with PMA, a phorbol
ester known to activate the NADPH oxidase directly
through protein kinase C (Fig 10A). Furthermore, the p38
MAPK inhibitor attenuated the effect of TNF-α induced
granule mobilization, as determined by a reduced expo-
sure of CR3 on the surface of cells challenged with TNF-α
in the presence of SB 203580 (Fig 10B). Hence, p38MAPK
is involved not only in the TNF-α-induced NADPH-oxi-
dase activation in adherent cells, but also in the priming
effects (degranulation and cytochalasin B-sensitivity)
induced by the cytokine.
Dilution effects on cytochalasin B induced activation Figure 6
Dilution effects on cytochalasin B induced activation Neutrophils were incubated in the presence of fMLF (10-7M; A) or 
TNF-α (25 ng/ml; B) for 20 min at 37°C and then diluted in measuring vials containing the same concentration (high; solid lines) 
or no agonist (low; dashed lines), respectively. The cells were then immediately challenged with cytochalasin B. The production 
of superoxide anion was measured by isoluminol-amplified CL as described above. The figure shows the kinetics of represent-
ative experiments and the ratios, determined from the peak response in the presence of high and low concentrations of 
agonist.
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Discussion
A prominent feature of TNF-α is its capacity to prime neu-
trophils to other stimuli. In this study, we show that TNF-
α-treated neutrophils are primed for activation by the
cytoskeleton-disrupting drug cytochalasin B. The
molecular mechanisms underlying priming of the
NADPH oxidase response have been extensively studied.
In previous reports, we have forwarded the hypothesis
that mobilization of receptors, stored within granules/ves-
icles, is a major mechanism involved in priming of the
neutrophil response [15-17]. Other proposed mecha-
nisms include alterations of intracellular signaling path-
ways (increased protein phosphorylation [28],
phospholipase activity [29], intracellular Ca2+  changes
[30]), cross-talk between Ca2+ increase and tyrosine phos-
phorylation [31], altered assembly of the oxidase [32],
and proteolytic processing of cell surface proteins [33].
Although we can not exclude that multiple mechanisms
Addition of non-primed cells to TNF-α primed cells and activation by cytochalasin B Figure 7
Addition of non-primed cells to TNF-α primed cells and activation by cytochalasin B. Neutrophils incubated for 20 
min at 37°C for 20 min were added to a population of TNF-α primed cells. The amount of superoxide release by the newly 
added cells was determined (A; dashed line). For comparision the NADPH-oxidase activity induced by cytochalasin B when 
added to the TNF-primed cells (A; solid line) is also shown. The NADPH-oxidase activity induced by cytochalasin B in a cell 
population where all the cells were primed with TNF-α for 20 min (B; solid line) was compared to that of a cell population 
where 50% of the cells were primed with TNF-α for 20 min and the other 50% for 1 min (B; dashed line). The production of 
superoxide anions was measured by isoluminol-amplified CL as described above. The figure shows the kinetics of representa-
tive experiments and the ratios between the peak responses in the populations are also given.
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may be involved in TNF-α-induced priming, it is impor-
tant to point out that a prerequisite for priming through
the mechanisms described above is that a second agonist
is required, in addition to the priming agent, in order to
disclose the increased potential for neutrophils to
respond.
The cytoskeleton disrupting molecule cytochalasin B has
generally been regarded as a substance which lacks the
ability to activate neutrophils by itself, and the results
described here could possibly be explained by an ability of
cytochalasin B to induce a state of receptor reactivation
[18]. This is defined as the transfer of a deactivated/desen-
sitized receptor into an actively signaling state, achieved
by uncoupling of the receptor from the cytoskeleton.
Using the ligand-receptor pair fMLF-FPR as a model, it has
been shown that the processing of neutrophil chemoat-
tractant receptors includes highly regulated events that
occur in a given chronological order. The binding of the
agonist to its inactive cell surface receptor (FPR) generates
an actively signaling receptor-ligand complex (FPR*).
Shortly after binding of the chemoattractant to its
receptor, the receptor-ligand complex associates with
actin or other cytoskeletal proteins [34-36], inducing a
physical segregation of the signaling G-protein and the
receptor into different plasma membrane domains [37].
This leads to termination of the response by a direct cessa-
tion of the transmembrane signals, and the receptor-lig-
and complex is thus deactivated/desensitized (FPR*des).
The addition of cytochalasin B to cells with such deacti-
vated/desensitized receptors leads to uncoupling of the
receptor-ligand complex from the cytoskeleton, resulting
in regained signaling capacity of the receptor (FPRre*),
and the signals generated activate the oxidase [18].
The cytochalasin B induced activation of the NADPH-oxi-
dase in TNF-α primed neutrophils is very similar to that
achieved by an uncoupling of FPR*des from the cytoskele-
ton and a transfer of the receptor into an FPRre* state. The
assumption that GPCRs are involved also in TNF-α/cyto-
chalasin B induced oxidase activity was validated by
experiments using pertussis toxin, a specific inhibitor of
the heterotrimeric G-proteins linked to all the neutrophil
chemoattractant receptors yet characterized [2]. The cyto-
chalasin B-induced oxidase activity in TNF-α primed cells
was clearly pertussis toxin sensitive; in contrast, the toxin
did not affect TNF-α induced mobilization of CR3 to the
cell surface, which is in agreement with the fact that the
TNF-α receptor itself is not a member of the GPCR family
[38]. It is interesting to note that cytoskeleton-dependent
receptor reactivation is not achieved with all neutrophil
GPCRs. FPR*des, FPRLl*des and C5aR*des were all reactivat-
able by cytochalasin B. No such reactivation was however
obtained with the occupied receptors for IL-8 and PAF.
Neither the IL-8-R*des nor the PAF-R*des could thus be
reactivated with cytochalasin B (Table 1). These data
suggest that these two receptor-ligand pairs should be
excluded from being responsible for the TNF-α induced
change in sensitivity for cytochalasin B, but more impor-
tantly the data also suggest that there are fundamental
differences with respect to signaling between different
groups of chemoattractant receptors. This is in agreement
with recently presented data describing distinct signaling
pathways for GPCRs that mediate directional migration
by chemoattractants, guiding the neutrophils out of the
vasculature (i.e., interleukins and lipid mediators) and
those that guide the cells through the interstitium to a site
of infection (i.e. bacterial chemoattractants and activated
complement factors) [39]. Our results suggest that TNF-α
induces a neutrophil state that shares basic the signaling
properties with the FPR*des, FPRLl*des and C5aR*des, i.e., a
state that is reactivated when the cytoskeleton is disrupted
by cytochalasin B.
Neutrophils contain known, and probably also unknown,
secretable chemoattractants [24,40], as well as known and
possibly not yet identified receptors for such agonists (i.e.,
CR3-upregulation in TNF-α primed neutrophils Figure 8
CR3-upregulation in TNF-α primed neutrophils. Neu-
trophils were incubated with TNF-α (25 ng/ml, 20 min, 37°C, 
solid line) and were paraformaldehyde-fixed, incubated with 
phycoerythrin-conjugated anti-CR3 antibodies (CD18/
CD11b) and analysed by flow cytometry and compared with 
control cells (dashed line). Representative histograms of 
binding are shown, and the inset shows the exposure of CR3 
on fMLF-primed neutrophils. The numbers indicate the mean 
fluorescence intensity as percent of control ± SD, n = 3.
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CXCR1 and 2 for IL-8 and FPRL1 for LL37). The combined
TNF-α/cytochalasin B-dependent activation process was
pertussis toxin sensitive suggesting that the activation
process involves a heterotrimeric G-protein, possibly (but
not known for certain) linked to a receptor. An attractive
hypothesis that directly explains our results would be that
TNF-α induces secretion of an endogenous agonist which
binds back to a neutrophil receptor sharing its basic sign-
aling properties with the cytoskeleton-regulated group of
GPCRs. This endogenous agonist would occupy its surface
receptors and being a ligand-receptor pair of the cytoskel-
eton-binding type, the receptors would then become
desensitized upon agonist binding and the cells would be
transferred into a cytochalasin B-activated state. Although
we can not exclude this possibility, the experimental evi-
dence presented is inconsistent with this scenario. On the
one hand pretreatment with secretagogues induces mobi-
lization of neutrophil storage organelles, but on the other
hand, such a mobilization is insufficient for induction of
the cytochalasin B sensitive state as illustrated by the
finding that IL8, a potent secretagogue (Fig 9), failed to
prime neutrophils for subsequent activation by cytochala-
sin B (Table 1). In addition, we assumed that provided
that a hypothetical agonist secreted in response to TNF-α
has a binding affinity for its receptor, that is of the same
magnitude as the hitherto identified/characterized neu-
trophil activators, it should be present in the extracellular
environment, but despite the use of several experimental
approaches we were unable to find any evidence for the
existence of such an agonist.
Over the past few years, studies on the biology of GPCR
have been focused on the activation achieved through
binding of a specific agonist to its receptor. It has, how-
ever, become increasingly clear that GPCRs can be trans-
ferred from a non-signaling R state to an actively signaling
R* state also in the absence of any bound ligand [19,41].
It is obvious that the R* state can not be constitutively
active, and irrespectively of whether the receptor reaches
the R* state following agonist binding or if this state is
reached independently of any activating agonist, the deac-
tivation mechanisms appears to be put in action. The
physical separation of the R* from the G-protein occur-
ring through a linkage of the receptor to the cytoskeleton,
constitute an important termination mechanism, and
R*des state can be reversed through an uncoupling from
the cytoskeleton [18]. The fact that we were unable to find
any secreted components that could fulfill the role of a
receptor agonist in the TNF-α/cytochalasin B dependent
activation system, suggests that TNF-α may transfer
neutrophil GPCR's to a cytoskeleton associated R*des state
independently of agonist binding.
CR3-upregulation in IL-8 and TNF-α primed neutrophils Figure 9
CR3-upregulation in IL-8 and TNF-α primed neutrophils. Neutrophils were incubated with or without IL-8 (100 ng/ml) 
or TNF-α (25 ng/ml) for 20 min at 37°C. The cells were then paraformaldehyde-fixed, incubated with phycoeryterin-conju-
gated anti-CR3 antibodies (CD18/CD11b), analysed by flow cytometry and compared with control cells. The data is calculated 
from the mean fluorescence intensity of each cell population and expressed as percentage of the value obtained in control cells, 
n = 6.
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Effects of SB203580 on TNF-α priming Figure 10
Effects of SB203580 on TNF-α priming. Neutrophils were primed by TNF-α (25 ng/ml, 20 min, 37°C) in the absence or 
presence of the p38 MAPK inhibitor SB203580 (1 µM). (A) The cells were stimulated with cytochalasin B (5 µg/ml) and the 
extracellular production of superoxide anion was measured by CL. The effect of SB203580 on PMA-induced superoxide anion 
production was used as control. (B) Neutrophils were incubated with TNF-α (25 ng/ml) in the absence or presence of 
SB203580 (1 µM)), or with SB203580 alone (20 min, 37°C) and were paraformaldehyde-fixed, incubated with phycoerythrin-
conjugated anti-CR3 antibodies (CD18/CD11b), analysed by flow cytometry and compared with control cells. Calculation 
were made from the mean fluorescence intensity of each cell population and expressed as percentage of the value obtained in 
control cells. The results are given as mean ± SE of three independent experiments.
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A transformation from R to R* can, thus, occur in the
absence of a specific ligand, but very little is known about
the regulatory mechanisms that determines the rate of
transfer or the levels of the two forms at equilibrium. The
R/R* equilibrium differs for individual wild-type isoforms
of a given receptor, and the ratio between the two forms
can also be changed both by defined point mutations
localized to several different intracellular receptor
domains, as well as by the degree of glycosylation of the
receptor [19]. It seems reasonable to hypothesize that the
R/R* transformation rate and/or ratio at equilibrium can
be changed not only through direct structural changes in
the receptor protein, but also indirectly through signals
generated by a second receptor such as the one for the
TNF-α (receptor communication), or through a direct
receptor-receptor interaction in the membrane.
Conclusions
Neutrophils triggered with TNF-α mobilize receptor stor-
ing organelles and concomitantly but independently, the
cells are primed to respond to the microfilament disrupt-
ing toxin cytochalasin B. These findings are suggestive of
two mechanisms involved in neutrophil priming by TNF-
α. While the enhanced response to fMLF is explained by
recruitment of new formyl peptide receptors to the cell
surface, the cytochalasin B-sensitive state is achieved
through a novel mechanism that transfers G-protein cou-
pled receptors to a primed state which is fully activated
when cytochalasin B uncouples the receptors from the
cytoskeleton. Such a reaction could possibly be induced
by an endogenous secreted receptor agonist. We were,
however, unable to find any components that could fulfill
the role of an agonist in the TNF-α/cytochalasin B
dependent activation system. The presented data support
the recently introduced concept that receptor activation
can occur independently of a specific receptor ligand [19].
Accordingly, we suggest that TNF-α transfers neutrophil
receptors to a desensitized and cytoskeleton associated
state independently of agonist binding.
Methods
Isolation of neutrophils
Leukocytes were isolated from freshly prepared leuko-
packs (The Blood Center, Sahlgrenska University Hospi-
tal, Göteborg) obtained from healthy blood donors. After
removal of erythrocytes through dextran sedimentation,
the leukocyte-rich supernatant was carefully layered onto
Ficoll-Paque (Lymphoprep, Nyegaard, Norway). After
centrifugation at 380 × g for 30 minutes, the pellet was
resuspended in Krebs-Ringer phosphate buffer (KRG, pH
7.3; 120 mM NaCl, 5 mM KC1, 1.7 mM KH2PO4, 8.3 mM
NaHPO4 and 10 mM glucose) supplemented with Ca2+ (1
mM) and Mg2+ (1.5 mM), and kept on melting ice until
used in experiments [42].
Neutrophil activators
The hexapeptide Trp-Lys-Tyr-Met-Val-Met-NH2
(WKYMVM) was synthesized and HPLC-purified by Alta
Bioscience (University of Birmingham, Birmingham,
United Kingdom). The formylated peptide N-formylme-
thionyl-leucyl-phenylalanine (fMLF), the chemotactic
fragment of complement factor 5 (C5a), platelet activat-
ing factor (PAF), and TNF-α were from Sigma Chemical
Co., St. Louis. Human recombinant IL-8 was provided by
R&D Systems, Oxon, UK. The peptide agonists were dis-
solved in dimethyl sulfoxide to 10-2M and stored at -70°C
until use. Further dilutions were made in KRG.
Neutrophil priming and NADPH-oxidase activity
Neutrophils (1–2 × l06cells/ml) were incubated at 37°C
for 5–40 minutes in the presence or absence (control) of
a priming agent. The NADPH-oxidase activity of these
cells was then recorded using luminol/isoluminol-
enhanced chemiluminescence (CL) systems [43]. The CL
activity was measured in a six-channel Biolumat LB 9505
(Berthold Co. Wildbad, Germany), using disposable 4-ml
polypropylene tubes with a 0.90-ml reaction mixture
containing 1–2 × 106 neutrophils. In order to differentiate
between intracellularly and extracellularly generated reac-
tive oxygen species, two different reaction mixtures were
used. Tubes used for the measurement of extracellular
release of superoxide anion contained neutrophils, horse-
radish peroxidase (HRP; a cell impermeable peroxidase; 4
U) and isoluminol (a cell impermeable CL substrate; 2 ×
10-5M). Tubes used for measurement of intracellular
generation of reactive oxygen species contained neu-
trophils, SOD (a cell impermeable scavenger for O2
-; 50
U), catalase (a cell impermeable scavenger for H2O2; 2000
U), and luminol (a cell permeable CL substrate; 2 × 10-
5M). The tubes were equilibrated at 37°C, after which the
stimulus (0.1 ml) was added. The light emission was
recorded continuously.
Determination of receptor exposure
The amount of fMLF-receptors expressed on the cell sur-
face in the different neutrophil populations was deter-
mined by incubating the cells with radiolabeled fMLF in
the presence or absence of unlabeled fMLF. Unbound
peptide was removed by centrifugation of the cells
through an oil layer. The oil layer which was composed of
a mixture of dibutylphtalate and dinonylphtalate (10:3, v/
v; 100 µl) was layered on top of 10 µl of urea (6 M) in
Eppendorf tubes. The radiolabeled peptide (50 µl
[3H]fMLF; 8 × 10-8M) was then layered on top of the oil
followed by 50 µl of unlabeled fMLF (4 × 10-5M) in KRG
or vehicle alone. Neutrophils (2 × 106, 100 µl) were added
to the fMLF-solution and the tubes were incubated on
melting ice for 1 h. After centrifugation at 9000 × g for 15
seconds in a Beckman microfuge (Beckman Instruments,
Fullerton, CA), the bottom of the centrifuge tubes (con-BMC Cell Biology 2004, 5 http://www.biomedcentral.com/1471-2121/5/21
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taining the pelleted cells) was excised and collected for
determination of radioactivity.
To measure surface exposure of CR3, the cells were labeled
with phycoerythrin-conjugated monoclonal antibodies
specific for CD11b (DAKO M741; 10 µl to a cell pellet of
106). The cells were examined by use of flow cytometry
(FACScan; Becton Dickinson, Mountain View, CA).
Deactivation and reactivation
In order to deactivate neutrophils to GPCR agonists, the
cells were first equilibrated for 10 min at 15°C. The ago-
nist, e.g., the chemoattractant fMLF (final concentration
10-7M) was added and the incubation was continued at
15°C for an additional 5 min [44]. The cells were then
transferred to 37°C for 5 minutes, and reactivation was
subsequently achieved by adding cytochalasin B (5 µg/
ml).
Reagents
Human recombinant TNF-α, fMLF, luminol, isoluminol,
cycloheximide, Pertussis toxin, SB 203580 and cytochala-
sin B were obtained from Sigma Chemical Co., St. Louis.
Superoxide dismutase (SOD), catalase and horse radish
peroxidase (HRP) were from Boehringer-Mannheim, Ger-
many. Radiolabeled fMLF was from Du Pont NEN (Bos-
ton, Mass).
Statistical analysis
The Student's t-test (two-tailed) was performed to deter-
mine statistical significance.
List of abbreviations
CD11b, cluster of differentiation number 11b; CL, chemi-
luminescence, GPCR, G-protein coupled receptor, CR3,
complement receptor 3, CXCR, the IL 8 (CXC cytokine)
receptor, C5a, the chemotactic split product from comple-
ment factor 5; C5aR, the C5a receptor, fMLF, formylmet-
leu-phe; FPR, the formyl peptide receptor; FPRL1, the
formyle peptide like receptor 1; IL-8, interleukin 8; SOD,
superoxide dismutase; TNF, tumor necrosis factor, TNFR,
the TNF-recepor; WKYMVM, Trp-Lys-Tyr-Met-Val-Met.
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